merck-keytruda

Keytruda + Inlyta combo beats Pfizer’s chemotherapy Sutent in renal cell carcinoma

pharmafile | February 12, 2019 | News story | Manufacturing and Production, Research and Development |  Cancer, MSD, Pfizer, inlyta, keytruda, pharma, renal cell carcinoma 

New data has been revealed on the efficacy of MSD’s Keytruda (pembrolizumab) in combination with Pfizer’s Inlyta (axitinib), showing it successfully reduced the risk of death by almost half in advanced renal carcinoma (RCC) patients compared to Pfizer’s chemotherapy drug Sutent.

Specifically, the combo reduced the risk of death in RCC by 47%, while risk of disease progression or death was reduced by almost 40%. In addition, overall response rate was 20% higher than that shown by Sutent.  

In light of the results, MSD’s Chief Medical Officer Dr Roy Baynes called Keytruda the “most broad spectrum anti-cancer drug ever”. The drug has so far secured FDA approval in 15 cancers and 10 tumour types, chalking up sales of $7.2 billion last year.

“This is a tremendous revolution in treatment of cancer patients,” Dr Baynes commented. “We are very humbled and gratified to be able to bring forward a medicine that has such a bigt effect on patients.”

Advertisement

It was confirmed that full results of the study will be presented at the Genitourinary Cancers Symposium in San Francisco this week.

Matt Fellows

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

The Gateway to Local Adoption Series

Latest content


Five Facts about COPD

October 11, 2026